We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

4 hedge funds and large institutions have $1.26M invested in Pasithea Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.9% more ownership

Funds ownership: 0% → 1.9% (+1.9%)

Holders
4
Holders Change
+4
Holders Change %
–
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

KTTA Hedge Fund Activity: Q3 2021 in Review

4 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2021, worth a combined $1.26M.

Buyers outnumbered sellers: 4 funds opened new KTTA positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Kepos Capital, opening a new position worth an estimated $1.21M.

  • 4 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $1.26M of Pasithea Therapeutics stock for Q3 2021.
  • 4 funds opened new Pasithea Therapeutics positions in Q3 2021 and 0 closed out, a net change of +4 holders.
  • The largest Pasithea Therapeutics buyer in Q3 2021 was Kepos Capital, an estimated $1.21M added.

Based on aggregated 13F filings for Q3 2021.